Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL893723 | 1.00 | HSD17B10 (0.56) | HSD17B10GAAALDH1A1SLC6A9CYP1A2 | |
| SCHEMBL3504659 | 1.00 | HSD17B10 (0.56) | HSD17B10GAAALDH1A1SLC6A9CYP1A2 | |
| SCHEMBL1065178 | 1.00 | HSD17B10 (0.56) | HSD17B10GAAALDH1A1SLC6A9CYP1A2 | |
| SCHEMBL21454626 | 1.00 | HSD17B10 (0.56) | HSD17B10GAAALDH1A1SLC6A9CYP1A2 | |
| SCHEMBL454245 | 1.00 | HSD17B10 (0.56) | HSD17B10GAAALDH1A1SLC6A9CYP1A2 | |
| SCHEMBL321552 | 1.00 | HSD17B10 (0.56) | HSD17B10GAAALDH1A1SLC6A9CYP1A2 | |
| SCHEMBL17512849 | 1.00 | HSD17B10 (0.56) | HSD17B10GAAALDH1A1SLC6A9CYP1A2 | |
| SCHEMBL21320722 | 0.97 | HSD17B10 (0.54) | HSD17B10GAAALDH1A1SLC6A9CYP1A2 | |
| SCHEMBL1661688 | 0.97 | — | — | |
| SCHEMBL661575 | 0.97 | HSD17B10 (0.58) | HSD17B10GAAALDH1A1SLC6A9CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 555 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026099626-A1 | METHODS AND SYSTEMS FOR MANUFACTURING RADIOPHARMACEUTICALS | NOVARTIS AG (CH) | 2026-05-15 | — | — | WO | claimed |
| CN-122005879-A | Modified GRPR antagonist peptides for cancer imaging and treatment | 慕尼黑工业大学 | 2026-05-12 | — | — | CN | claimed |
| US-20260069726-A1 | ZWITTERIONIC COMPOUNDS AND USES THEREOF | UNIV SASKATCHEWAN (CA) | 2026-03-12 | — | — | US | claimed |
| EP-4642489-A1 | CONJUGATE AND USES THEREOF | Full-Life Technologies HK Limited (HK) | 2025-11-05 | — | — | EP | claimed |
| WO-2025202114-A1 | RADIOSENSITISING PEPTIDE COMPLEX | GCS INSTITUT DE CANCEROLOGIE STRASBOURG EUROPE (FR) | 2025-10-02 | — | — | WO | claimed |
| US-20250288702-A1 | LABELING PRECURSORS WITH SQUARIC ACID COUPLING | Telix Pharmaceuticals Limited (AU) | 2025-09-18 | — | — | US | claimed |
| WO-2025125621-A1 | CANCER-ASSOCIATED PROTEIN-TARGETED STRONG OR COVALENTLY BINDING PRECURSOR COMPOUNDS AND RADIOTRACERS | RADIOVAXX GMBH (DE) | 2025-06-19 | — | — | WO | claimed |
| WO-2024212001-A9 | 2,4-DIHYROXY-5-ISOPROPYLPHENYL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF EFFECTIVE AS EXTRACELLULAR HSP90, (EHSP90)-TARGETED RADIOPHARMACEUTICALS USEFUL IN THE TREATMENT OF CANCER | Fusion Pharmaceuticals Inc. (CA) | 2025-06-19 | — | — | WO | claimed |
| US-20250177581-A1 | NTSR1-TARGETED RADIOPHARMACEUTICALS AND DNA DAMAGE RESPONSE INHIBITOR COMBINATION THERAPY | FUSION PHARMACEUTICALS INC (CA) | 2025-06-05 | — | — | US | claimed |
| US-20250163239-A1 | Metal-Labeled Polymer Microbeads with Control Over Labeling Level | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2025-05-22 | — | — | US | claimed |
| US-20140234211-A1 | SUPRAMOLECULAR AGGREGATES CONTAINING AMPHIPHILIC MONOMERS, CHELATING AGENTS AND PEPTIDES FOR USE FOR DRUG DELIVERY AND AS CONTRAST AGENTS | INVECTORS S.R.L. (IT) | 2014-08-21 | — | — | US | claimed |
| US-20130302243-A1 | RADIOLABELED NANOSYSTEM, PROCESS FOR THE PREPARATION THEREOF AND ITS USE | BBS NANOMEDICINA ZRT. (HU) | 2013-11-14 | — | — | US | claimed |
| EP-1257575-B1 | RADIOLABELED VASOACTIVE INTESTINAL PEPTIDE ANALOGS FOR DIAGNOSIS AND RADIOTHERAPY | DABUR RES FOUNDATION (IN) | 2007-02-28 | — | — | EP | claimed |
| US-6706252-B1 | Method of treating disease with radioisotopes conjugated to bioactive substances | RX/IBR CORPORATION | 2004-03-16 | — | — | US | claimed |
| US-6608174-B1 | Of given amino acid sequence; radionuclides; use as scintigraphic imaging agents for visualization of tumors and metastasis | DABUR RESEARCH FOUNDATION (IN) | 2003-08-19 | — | — | US | claimed |
| EP-1257575-A1 | RADIOLABELED VASOACTIVE INTESTINAL PEPTIDE ANALOGS FOR DIAGNOSIS AND RADIOTHERAPY | Dabur Research Foundation (IN) | 2002-11-20 | — | — | EP | claimed |
| WO-2001060863-A1 | RADIOLABELED VASOACTIVE INTESTINAL PEPTIDE ANALOGS FOR DIAGNOSIS AND RADIOTHERAPY | DABUR RESEARCH FOUNDATION (IN) | 2001-08-23 | — | — | WO | claimed |
| US-5776894-A | Chelated somatostatin peptides and complexes thereof, pharmaceutical compositions containing them and their use in treating tumors | NOVARTIS AG (CH) | 1998-07-07 | — | — | US | claimed |
| US-5753627-A | Use of certain complexed somatostatin peptides for the invivo imaging of somatostatin receptor-positive tumors and metastasis | NOVARTIS AG (CH) | 1998-05-19 | — | — | US | claimed |
| EP-0498771-A2 | MSH peptide derivatives | SANDOZ LTD. (CH) | 1992-08-12 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250177581-A1 | NTSR1-TARGETED RADIOPHARMACEUTICALS AND DNA DAMAGE RESPONSE INHIBITOR COMBINATION THERAPY | NTSR1, NTSR2, NPSR1 | HSD17B10 4478/4885GAA 2524/4885ALDH1A1 3190/4885 |
| US-20140234211-A1 | SUPRAMOLECULAR AGGREGATES CONTAINING AMPHIPHILIC MONOMERS, CHELATING AGENTS AND PEPTIDES FOR USE FOR DRUG DELIVERY AND AS CONTRAST AGENTS | GRPR, BRS3, BID | HSD17B10 4833/4885GAA 3593/4885ALDH1A1 4807/4885 |
| US-20260069726-A1 | ZWITTERIONIC COMPOUNDS AND USES THEREOF | CA13, SLCO2B1, SLCO2A1 | HSD17B10 2357/4885GAA 2122/4885ALDH1A1 1600/4885 |
| US-20250288702-A1 | LABELING PRECURSORS WITH SQUARIC ACID COUPLING | SCLY, SRRT, CS | HSD17B10 2187/4885GAA 32/4885ALDH1A1 1343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.